Elizabeth A Griffiths
Affiliation: Roswell Park Cancer Institute
- A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemiaElizabeth A Griffiths
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Sts, Buffalo, NY 14263, United States Electronic address
Leuk Res 43:44-8. 2016..At the dose and schedule tested, this combination did not appear to result in improved CR over single agent AraC for r/r AML. ..
- Epigenetic therapies in MDS and AMLElizabeth A Griffiths
Roswell Park Cancer Institute, Buffalo, NY, USA
Adv Exp Med Biol 754:253-83. 2013....
- Myelodysplastic syndromes and autoimmune diseases--case series and review of literatureOmar Al Ustwani
Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA
Leuk Res 37:894-9. 2013..The mechanism(s) of the association between AD and MDS are discussed. Treatment could be targeted against AD, MDS or both, though based on recent reports, treating MDS with hypomethylating agents alone could improve the associated AD. ..
- Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years oldNeha Gupta
Department of Medicine, SUNY UB School of Medicine, Buffalo, New York
Am J Hematol 90:639-46. 2015..should drive treatment decisions. Prospective randomized trials to determine the optimal induction approach for specific patient subsets are needed...
- Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid LeukemiaMonica R Muppidi
Leukemia Service, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY Electronic address
Clin Lymphoma Myeloma Leuk 15:S73-9. 2015..FLT-3 inhibitors such as sorafenib have been studied as a single agent and in combination with conventional chemotherapy or azacytidine with fair responses...
- Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of ageCarlos E Vigil
Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States
Leuk Res 37:1468-71. 2013..Six (28.6%) patients achieved complete remission including three (21.4%) of 14 patients with unfavorable AML. The median disease-free survival was 6.8 months and the median overall survival was 11.2 months. ..
- Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapyLin Mei
Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Blood Rev 29:243-9. 2015..Incorporating recent pharmacogenetic data, mainly from pediatric ALL, will provide novel perspective of predicting response and toxicity in both pediatric and adult ALL therapies. ..
- Omacetaxine mepesuccinate in chronic myeloid leukemiaOmar Al Ustwani
Roswell Park Cancer Institute, Department of Medicine, Leukemia Section, Elm and Carlton Street, Buffalo, NY 14263, USA 001 716 845 8447 001 716 845 2343
Expert Opin Pharmacother 15:2397-405. 2014..Omacetaxine mepesuccinate is a semisynthetic derivative of HHT with known clinical activity in relapsed or refractory CML following TKI therapy...
- Polo-like kinase inhibitors in hematologic malignanciesChetasi Talati
Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA Electronic address
Crit Rev Oncol Hematol 98:200-10. 2016..Novel approaches, such as Plk inhibitors, are urgently needed for these patients. Here, we provide a comprehensive overview of the current state of development of Plk inhibitors for the treatment of hematologic malignancies. ..
- Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignanciesBritny Rogala
Roswell Park Cancer Institute, Department of Pharmacy, Elm and Carlton Streets, Buffalo, NY 14263, USA
Expert Opin Biol Ther 15:895-908. 2015..Success comes at the cost of immunological toxicities rarely encountered with previous therapies and challenging administration logistics requiring clinical expertise...
- How we will treat chronic myeloid leukemia in 2016Chetasi Talati
Internal Medicine, University at Buffalo, Buffalo, NY, USA
Blood Rev 29:137-42. 2015..We hope that our message will open communication between providers, insurance companies and healthcare authorities to offer the best care for our patients...
- Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemiaHun Ju Lee
Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York
Cancer 120:521-9. 2014..Several studies have suggested that low 25(OH) vitamin D3 levels may be prognostic in some malignancies, but no studies have evaluated their impact on treatment outcome in patients with acute myeloid leukemia (AML)...
- Interpretation of cytogenetic and molecular results in patients treated for CMLCarlos E Vigil
Roswell Park Cancer Institute, Buffalo, NY 14263, United States
Blood Rev 25:139-46. 2011..The relationship between a complete cytogenetic response at 12 months and long-term PFS supports a role for second-generation TKIs as first-line treatment of newly diagnosed chronic-phase CML...